By understanding complex biology through cutting-edge AI, we identify new treatments, de-risk and accelerate clinical trials, and build diagnostic tools to reduce time to impact for patients. Owkin works with top academic centers to curate, enrich and generate deep, multimodal data that is AI ready.
We apply AI to multimodal, KOL-curated data to subtype patients and identify novel biomarkers to inform drug discovery, de-risk clinical trials and develop and deploy diagnostics in clinical practice. We use AI to identify biomarkers from patient biology, match patient subpopulation with candidate target, and match drugs with new indications or subpopulations of existing indications.
We combine machine learning methodologies, patient data, and innovative modalities to increase the probability of success of clinical trials. This means more patients can benefit from targeted therapies.
Owkin is differentiated by a focus on improving our fundamental understanding of disease mechanics through data, biology and AI. Powered by multimodal patient data, our AI models match novel targets with patient subgroups to identify the best treatments.
We merge wet lab experiments with advanced AI techniques to create a powerful feedback loop for accelerated discovery and innovation. Partnership opportunities and how we work with top academic centers to curate, enrich and generate deep, multimodal data. Deep learning to reduce sample size requirement for adjuvant HCC trials. We are a community of diverse people bringing our energy and skills to find the right treatment for every patient.
